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Abstract
Objective: Starvation induces a complex neuroendocrine response in humans thought to have evolved
to defend against reduced energy intake. The drop in leptin levels observed during fasting has been
implicated as a factor that triggers this adaptive response. To explore this hypothesis, we executed
a randomized, double-blind, placebo-controlled study to investigate whether elevated leptin levels
using long-acting pegylated human recombinant leptin (PEG-OB) influenced the neuroendocrine
responses to semi-starvation in human subjects.
Design: Twenty-four overweight male subjects (mean^S.E.M.; 34.8^1.3 yrs; 28.8^0.5 kg/m2) were
prescribed a very low energy diet (2.1 MJ/day) to induce a state of semi-starvation for the next
46 days. In addition, all subjects received a weekly treatment of 80 mg PEG-OB or matching placebo.
Hormone measurements were performed throughout the study period and included 5-h frequent hor-
mone samplings and 24-h urine collections.
Results: Weekly subcutaneous administration of PEG-OB led to significant additional weight loss
(2.8 kg) but it did not reverse the fasting-induced changes in the thyroid, corticotropic, somatotropic
axes and sympathetic nervous system activity. However, after adjustment for weight loss, the drop in
mean luteinizing hormone levels was attenuated in the PEG-OB group compared with the placebo
group.
Conclusions: These results suggest that a reduced level of leptin accompanying food restriction might
be a component of the fasting-induced neuroendocrine inhibition of the human reproductive axis.
European Journal of Endocrinology 148 649–655
Introduction
Starvation or severe energy restriction rapidly evokes
several neuroendocrine adaptive responses in humans.
These responses are thought to have survival value in
periods of inadequate energy intake. Among these
neuroendocrine adaptations is a suppression of both
the reproductive and thyroid axes while selected com-
ponents of the corticotropic and somatotropic axes
are stimulated (1, 2). The mechanisms that trigger
these adaptive responses to energy restriction are still
not clear.
Leptin, the protein hormone encoded by the ob gene,
is primarily secreted from adipose tissue and plays an
important role in body weight homeostasis by regulat-
ing food intake and energy expenditure (3–5). Serum
leptin concentrations are directly proportional to adipo-
cyte mass and are reduced in humans and animals that
have lost body fat, or are energy-restricted (6).
Some investigators have suggested that leptin has a
broader physiological role and evolved as a mediator
of the adaptations to fasting, and thus promotes
the chances of survival during periods of starvation
(2, 7). In favor of this hypothesis is the fact that
during fasting leptin levels drop rapidly and out of pro-
portion to fat mass changes (8). In addition, leptin
administration to rodents attenuates many of these
fasting-induced neuroendocrine changes in gonadal,
adrenal, and thyroid axes (7, 9). In male non-human
primates conflicting reports exist regarding the effect
of peripheral infusion of leptin during a short-term
fast. Reversal of the inhibitory effects of fasting on gon-
adotropin release occurred in one study while no effect
was found in two others (10 –12). In one study, intra-
venous replacement with homologous leptin did not
reverse the acute changes in growth hormone (GH)
and cortisol secretion observed with fasting in the
adult male macaque (12).
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One approach to study whether the neuroendocrine
effects of leptin administration to animals during
fasting can be extended to humans is to administer
exogenous leptin in conditions associated with a
(relative) deficiency or absence of leptin, such as
during severe energy restriction.
Therefore, we undertook a randomized, double-blind,
placebo-controlled study to investigate whether
elevated leptin levels using long-acting pegylated
recombinant leptin (PEG-OB) were able to attenuate
the neuroendocrine adaptations to semi-starvation
induced by a very low energy diet (VLED) in healthy
overweight male subjects.
Subjects and methods
Subjects
Twenty-four healthy overweight male volunteers were
recruited by local advertizing, screened and enrolled
in the study after execution of written informed con-
sent. The study was approved by the Medical Ethical
Committee of the Maastricht University. Overweight
and mildly obese men aged 18–45 yrs and with a
body mass index (BMI) between 25 and 32 kg/m2
were eligible for inclusion. Additional inclusion criteria
were: detailed medical and psychiatric histories and a
physical examination with negative findings, including
a normal adult sexual maturation, a normal 12-lead
resting electrocardiogram, no medical condition pre-
sent, no use of prescription medication, no smoking
and no transmeridian travel in the previous 4 weeks.
Each participant had normal biochemical tests of
renal, hepatic, metabolic and hematological function,
and morning fasting serum concentrations of insulin,
cortisol, insulin-like growth factor-1 (IGF-1), thyroid
stimulating hormone (TSH), prolactin (PRL), and total
testosterone within the normal ranges. Subjects with
a history or presence of drug abuse or alcoholism,
atopy or hypersensitivity to pegylated proteins and
with a weight loss of more than 3 kg in the previous
3 months were excluded from the study.
Study design
This single center trial had a prospective, randomized,
double-blind, placebo-controlled group design. After
screening, 24 subjects were selected and enrolled in the
trial. The study was divided into three phases:
a) baseline characterization (day 214, 28 and 1);
b) PEG-OB or placebo treatment and a VLED for 46 days
(day 1 to 46); and c) follow-up for 2 weeks (day 50 and
57). Baseline characterization consisted of a 5-h frequent
blood sampling protocol (day214) and a 24-h urine col-
lection (day 28) to measure the 24-h excretion of nor-
epinephrine (NE) performed in the 2 weeks before the
start of the diet and treatment period. All subjects were
asked to maintain a constant body weight until
the beginning of the diet and treatment phase and their
normal levels of physical activity throughout the study
period. Subjects were stratified and matched into pairs
according to age, BMI, fasting serum leptin and insulin
concentration to achieve balanced treatment groups.
Randomization numbers for subjects were generated
and incorporated into the double-blind labeling by an
independent third party. At the start of the treatment
period (day 1) all subjects were prescribed a VLED to
induce a state of semi-starvation for the next 46 days.
The VLED (Modifast, Novartis, Breda, The Netherlands)
provides 2.1 MJ daily and is a protein enriched formula
diet (containing 44, 14, and 42% of energy as protein,
fat and carbohydrate, respectively). The dietary prescrip-
tion was discussed every week with a dietician. Adher-
ence to the diet was confirmed by measurements of
body weight loss. Treatment consisted of either weekly
80 mg PEG-OB (8 ml, 10 mg ml21; produced and pro-
vided by Hoffmann-La Roche Inc., Nutley, New Jersey)
or matching placebo (8 ml) given s.c. in the para-umbili-
cal region during the VLED period. Subjects returned in a
fasting state on day 8, 15, 22, 29, 36, and 43 to the lab-
oratory to receive treatment after weight and vital signs
(pulse, respiratory rate, and blood pressure) were
recorded. Blood samples were drawn for safety labora-
tory tests and hormone measurements on day 1, 8, 15,
25, and 46. On day 24 the 24-h urine collection and
on day 25 the 5-h frequent blood sampling protocol
were repeated. After the treatment period (day 46) all
subjects received less formula diet and were instructed
to supplement this with a free choice of habitual food
items in order to gradually increase their energy intake
over the next 2 weeks. Vital signs and body weight
during this follow-up period were measured on day 50
and 57. Safety was monitored by documentation of
adverse events and recording of vital signs at each visit.
In addition, urine analysis and routine measurements
of serum chemistry and blood cell counts were conducted
regularly throughout the study. Standard clinical chem-
istry and blood cell counts were conducted at the certified
central laboratory of the University Hospital Maastricht,
The Netherlands.
PEG-OB
Recombinant methionyl human leptin has a reported
average terminal half-life of approximately 4 h in
humans, which requires daily administration to
obtain sustained blood levels (13). Modification of
proteins through covalent linkage of polyethylene
glycol polymers to the protein has resulted in reduced
immunogenicity and increased serum half-life for a
number of proteins (14). Recombinant native human
leptin, expressed and purified from Escherichia coli,
was chemically conjugated to a species of branched
polyethylene glycols (PEGs) with an average molecular
weight of 42 kDa in a 1:1 ratio. The result was a glob-
ular PEG-native human leptin polymer (PEG-OB) with
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increased molecular size. PEG-OB at a concentration of
10 mg/ml was placed in sterile glass vials containing
1.3 ml. Preclinical studies with PEG-OB indicate an
extended half-life (.48 h) and efficacy for reduction
of food intake and body weight in animals (15). Our
previous study in obese male subjects clearly showed
sustained elevated blood levels following weekly s.c.
dosing of PEG-OB in humans. Mean peak serum
PEG-OB concentrations were achieved 72 h after
dosing, followed by a return to the elevated pre-dose
levels after 1 week (16).
Hormone measurements
Venous blood was sampled on day 1, 8, 15, 25, and 46
after an overnight fast and allowed to clot for 20 min at
room temperature. Immediately after clotting the
samples were put on ice and serum was extracted by cen-
trifugation. The sera obtained were frozen in liquid nitro-
gen and stored at 280 8C for later measurements of
serum cortisol, insulin, IGF-1, free 3,5,30-triiodothyro-
nine (FT3), and free thyroxine (FT4). Mean 5-h hormone
levels were determined using a 5-h frequent blood
sampling protocol. In both the fed (day 214) and the
energy restricted (day 25) states, blood sampling was
carried out at 10-min intervals for 5 h beginning at
0800 h, at least 1 h after venapuncture. Blood was with-
drawn through an indwelling i.v. catheter placed into an
antecubital vein and collected with aprotinin (Trasylol,
10 000 Kallikrein inhibiting U/l; Bayer, Etobicoke,
Canada). Subjects remained in bed during sampling
and daytime naps were not allowed. Serum concen-
trations of cortisol, GH, luteinizing hormone (LH), follicle
stimulating hormone (FSH), TSH, PRL, total testoster-
one, sex hormone binding protein (SHBG) and albumin
were assayed in a single 5-h pool of serum.
Assays
The serum concentrations of cortisol, insulin, IGF-1,
FT3, FT4, GH, LH, FSH, TSH, PRL, total testosterone,
SHBG and albumin were all measured at the certified
central laboratory of the University Hospital Maas-
tricht. Serum cortisol was measured with a lumines-
cence enzyme-immunoassay ((LEIA), Immulite 200,
DPC, Los Angeles, USA), which has a sensitivity of
25 nmol/l and a reproducibility better than 10%.
Serum insulin was measured by an immunofluori-
metric sandwich assay ((IFMA), Autodelfia, Perkin
Elmer, Turku, Finland), which has a sensitivity of
1.4 mU/l and a reproducibility better than 6%.
Serum IGF-1 was measured by IRMA (Nichols Institute
Diagnostics, San Juan Capistrano, USA), which has a
sensitivity of 17 ng/l and a reproducibility better
than 15%. FT3 and FT4 were measured by two-step
fluoroimmunoassay ((FIA), Autodelfia), which has a
sensitivity of 0.04 pmol/l and a reproducibility better
than 4% for FT3 and a sensitivity of 1.3 pmol/l and a
reproducibility better than 4% for FT4. Serum GH
was measured by IFMA, which has a sensitivity of
0.1 mU/l and a reproducibility better than 7%.
Serum LH was measured by IFMA, which has a sensi-
tivity of 0.01 U/l and a reproducibility better than 3%.
Serum FSH was measured by IFMA, which has a sen-
sitivity of 0.2 U/l and a reproducibility better than
10%. Serum TSH was measured by IFMA, which has
a sensitivity of 0.012 mU/l and a reproducibility
better than 2%. Serum PRL was measured by IFMA,
which has a sensitivity of 0.0005 U/l and a reproduci-
bility better than 6%. Total serum testosterone was
measured by radioimmunoassay (DPC), which has a
sensitivity of 0.7 nmol/l and a reproducibility better
than 10%. Serum SHBG was measured by LEIA,
which has a sensitivity of 1 nmol/l and a reproducibil-
ity better than 4.5%. Free testosterone was calculated
from serum total testosterone, SHBG, and albumin
according to Swinkels et al. (17, 18) using the equili-
brium constants of testosterone to SHBG and albumin
to testosterone derived from Dunn et al. (19). Urinary
NE was determined by HPLC using the ClinRep kit
from Recipe (Munich, Germany). Total leptin concen-
trations (endogenous leptin plus PEG-OB) were
measured according to the method described pre-
viously (16).
Statistics
Data were analyzed using two-factor repeated-
measures ANOVA to compare differences in parameters
across the two groups over time. When significant
differences were found, a post hoc Scheffe’s procedure
was used to determine the location of the difference.
A multiple-linear regression model with the percentage
change in 5-h mean hormone concentrations from
baseline as the dependent variable and the percentage
change in weight and treatment status as independent
variables was used to analyze the difference in percen-
tage change in 5-h mean hormone concentrations from
baseline between both treatment groups, adjusted for
the independent variables. All statistical tests were
two-sided and significance was defined as P , 0.05.
All data are presented as means^S.E.M., unless other-
wise indicated.
Results
The characteristics of the subjects before the interven-
tion are presented in Table 1. The parameters used to
match subjects into pairs were not different and
balanced treatment groups were achieved. The baseline
hormone levels of the 12 subjects randomized to each
treatment group were similar. All subjects in the trial
were of Caucasian origin. Two subjects of the placebo
group dropped out voluntarily after 1 week because
they were not able to maintain the strict VLED
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regime. However, baseline characteristics of the two
groups remained comparable (data not shown). As
this study was a part of a greater study, results on
body weight, body composition, energy expenditure
and appetite have been published elsewhere (20). In
summary, at the end of the treatment period (day
46), weight loss was 14.6^0.8 kg in the PEG-OB
group, compared with 11.8^0.9 kg in the placebo
group (P ¼ 0.027). Significant reductions in appetite
were observed in the PEG-OB group however.
Table 2 shows the effect of energy restriction and
treatment on cortisol, FT3, FT4, IGF-1, insulin and
total leptin measured on day 1, 8, 15, 25, and 46. In
the first 3 weeks of the study cortisol levels increased
significantly from initial values in the PEG-OB group.
However, the rise of cortisol levels in the placebo
failed to reach significance. At the end of the treatment
period (day 46) cortisol fell below baseline levels in both
groups. FT3 declined significantly in the first 3 weeks
of study in both groups but the fall remained significant
in the PEG-OB group on day 46 only. FT4 levels were
increased in the placebo and PEG-OB groups during
the whole study, but only on days 8 and 15 was this
rise significantly different from the baseline. IGF-1
declined similarly in both groups to levels well below
the normal range during the study and reached a mini-
mum on day 25. Insulin levels declined from baseline in
both groups and remained significantly reduced
throughout the study. Urinary excretion of NE fell
from 54.5^3.4mg/24-h to 42.3^3.5mg/24-h in the
placebo group and from 51.5^4.3mg/24-h to
44.6^5.4mg/24-h in the PEG-OB group. No significant
differences were observed in levels of cortisol, FT3, FT4,
IGF-1, insulin and 24-h urinary NE excretion between
treatment groups over time.
Food restriction for 6 weeks by means of a VLED
reduced circulating leptin levels by 72% to
2.0^0.2 ng/ml in the placebo group (P , 0.001).
Following weekly s.c. dosing, sustained serum levels
of total leptin (endogenous leptin plus PEG-OB),
measured just before the next dose on day 8 and 15,
ranging from 950 to 3700 ng/ml were observed. Peak
total leptin concentrations on day 25 and 46,
measured 72 h after s.c. injection, ranged from
2300 to 6050 ng/ml.
The 5-h mean concentrations of serum cortisol, GH,
LH, FSH, TSH, PRL, total testosterone, SHBG, albumin
and estimated free testosterone on both study days
(days 214 and 25) for the two treatment groups are
shown in Table 3. Serum 5-h mean cortisol, TSH,
FSH and albumin levels were unchanged by energy
restriction and treatment in both groups. The 3 weeks
of semi-starvation resulted in a more than 4-fold
increase in the mean (5-h) serum GH concentrations
and an approximately 2-fold increase in mean SHBG
levels in all subjects. In contrast to the group receiving
PEG-OB, mean LH and PRL levels decreased signifi-
cantly in the placebo group. Mean total testosterone
levels increased significantly in the PEG-OB treatment
group but remained unaltered in the placebo group.
Calculated free testosterone concentrations declined
significantly in both the placebo and PEG-OB groups.
There was no significant difference in the delta or per-
cent change from baseline of 5-h mean concentrations
of serum cortisol, GH, LH, FSH, TSH, PRL, total testos-
terone, SHBG, albumin, and estimated free testosterone
between the groups.
A multiple-linear regression model with the
percentage change in 5-h mean hormone concen-
trations from baseline as a dependent variable and
the percentage change in weight and treatment status
as independent variables was used to analyze the differ-
ences between both treatment groups, defined by the
binary variable group. The percentage change in 5-h
mean LH concentrations of the PEG-OB group, plotted
as a function of percentage change in weight, resulted
in a positive relationship, i.e. a regression line that
was superimposed on the regression line of the placebo
group (Fig. 1). The regression line of the PEG-OB group
was significantly different from the regression line of
the placebo group (P ¼ 0.03). The percentage change
in 5-h mean LH concentrations adjusted for percentage
weight loss resulted in a reduced decrease in percentage
change in 5-h mean LH concentrations for the PEG-OB
Table 1 Baseline characteristics of the 24 subjects at the screening.
Characteristic Placebo (n ¼ 12) PEG-OB (n ¼ 12)
Age (years) 34.9^1.3 (24.0–40.0) 34.6^1.2 (26.0–41.0)
Weight (kg) 95.0^3.2 (77.2–113.9) 97.1^1.8 (87.5–106.6)
BMI (kg/m2) 28.6^0.5 (25.2–31.2) 28.9^0.4 (27.3–31.2)
Leptin (ng/ml) 7.3^0.9 (4.3–16.3) 7.0^0.8 (2.3–12.9)
Insulin (mU/l) 9.7^1.8 (4.0–26.0) 7.8^1.3 (1.9–17.0)
Cortisol (nmol/l) 333^26 (181–478) 349^34 (208–551)
IGF-1 (ng/ml) 166^11 (120–260) 177^11 (122–244)
TSH (mU/l) 1.6^0.1 (0.9–2.5) 1.5^0.2 (0.7–2.5)
PRL (U/l) 0.18^0.02 (0.12–0.30) 0.17^0.02 (0.09–0.31)
Total testosterone (nmol/l) 15.4^1.0 (9.0–21.4) 15.3^0.8 (10.0–21.7)
No statistical significant differences were found between both groups.
Data are presented as means^S.E.M.
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group compared with the placebo group. For the
complete study sample, both independent variables
accounted for 31% of the variance in mean 5-h
serum LH concentrations.
Discussion
We previously reported that exogenous leptin induces
additional weight loss in humans under severe
energy-restricted conditions by reducing appetite. In
the present report, we studied the effect of elevated
leptin levels using long-acting PEG-OB on the
neuroendocrine responses to severe energy-restriction
in human subjects.
Introducing a state of semi-starvation in this study
triggered an array of neuroendocrine responses similar
to those previously reported (21). Changes in the
thyroid (FT3 and FT4), corticotropic (cortisol) and
somatotropic axes (GH and IGF-1) paralleled the
severity of the energy deficit and were therefore more
pronounced (but not significantly different) in the
PEG-OB group, which lost significantly more weight.
In addition, PEG-OB treatment did not prevent the
inhibition of the sympathetic nervous system activity,
which normally occurs during energy restriction. The
suppression in several reproductive hormones (LH,
PRL, and estimated free testosterone with the exception
of FSH) tended to be reduced in the PEG-OB treated
group but failed to reach significance. However, after
adjustment for weight loss using multiple linear
regression, the drop in mean LH levels was attenuated
in the PEG-OB group compared with the placebo group.
A recent study reported reversal of the effects of sus-
tained weight-reduction on circulating concentrations
of thyroid hormones (T3 and T4 but not TSH) in four
subjects by a low dose of exogenous leptin (22). In
contrast, our study failed to demonstrate an effect of
leptin administration on the weight-loss decline in
FT3. The findings of this study are in line with the
characteristics of two human syndromes associated
with absent or very low leptin levels.
Patients with total leptin deficiency or non-func-
tional leptin receptors have been shown to be markedly
hyperphagic and the majority of these rare very obese
patients identified until now fail to attain normal
adult reproductive capabilities (23 –25). Daily s.c.
recombinant human leptin treatment of a young very
obese girl with a mutated ob gene caused rapid and
progressive reductions in body weight as a result of
decreased appetite and food-seeking behavior.
Furthermore, after 1 year of treatment with a low
dose of leptin, the appearance of pulsatile nocturnal
changes in LH was noted, which suggested the onset
of early puberty (26).
Four months of leptin replacement in seven
female patients with severe lipodystrophy and leptin
deficiency improved menstrual abnormalities and lowT
a
b
le
2
C
h
a
n
g
e
s
th
ro
u
g
h
o
u
t
th
e
in
te
rv
e
n
ti
o
n
in
e
n
d
o
c
ri
n
e
m
e
a
s
u
re
s
.
C
o
rt
is
o
l
(n
m
o
l/
l)
F
re
e
T
3
(p
m
o
l/
l)
F
re
e
T
4
(p
m
o
l/
l)
IG
F
-I
(n
g
/m
l)
In
s
u
li
n
(m
U
/l
)
T
o
ta
l
le
p
ti
n
†
(n
g
/m
l)
D
a
y
P
la
c
e
b
o
(n
¼
1
0
)
P
E
G
-O
B
(n
¼
1
2
)
P
la
c
e
b
o
(n
¼
1
0
)
P
E
G
-O
B
(n
¼
1
2
)
P
la
c
e
b
o
(n
¼
1
0
)
P
E
G
-O
B
(n
¼
1
2
)
P
la
c
e
b
o
(n
¼
1
0
)
P
E
G
-O
B
(n
¼
1
2
)
P
la
c
e
b
o
(n
¼
1
0
)
P
E
G
-O
B
(n
¼
1
2
)
P
la
c
e
b
o
(n
¼
1
0
)
P
E
G
-O
B
(n
¼
1
2
)
D
a
y
1
3
0
3
^
5
1
2
6
5
^
2
7
6
.1
^
0
.3
6
.0
^
0
.1
1
2
.7
^
0
.5
1
4
.1
^
0
.5
1
5
3
^
1
1
1
6
5
^
1
0
9
.4
^
1
.0
7
.2
^
0
.8
7
.1
^
0
.8
7
.6
^
1
.2
D
a
y
8
3
8
3
^
2
9
4
2
2
^
3
4
c
5
.0
^
0
.2
b
4
.8
^
0
.1
c
1
3
.9
^
0
.4
b
1
5
.4
^
0
.4
c
1
4
9
^
9
1
4
0
^
1
0
b
4
.5
^
0
.7
c
3
.4
^
0
.6
c
3
.4
^
0
.6
c
1
8
2
8
^
1
8
3
c
D
a
y
1
5
3
5
4
^
2
6
4
1
3
^
2
7
b
5
.0
^
0
.2
b
5
.2
^
0
.3
b
1
4
.1
^
0
.4
b
1
5
.8
^
0
.7
b
1
2
9
^
1
3
1
2
9
^
9
c
5
.0
^
1
.1
a
3
.2
^
0
.5
c
3
.1
^
0
.5
c
2
7
7
7
^
1
9
4
c
D
a
y
2
5
3
9
5
^
3
4
3
9
3
^
2
3
c
5
.2
^
0
.2
b
5
.0
^
0
.2
c
1
3
.4
^
0
.5
1
5
.0
^
0
.5
1
2
1
^
1
1
b
1
1
6
^
1
1
c
3
.4
^
0
.6
c
2
.2
^
0
.4
c
2
.1
^
0
.3
c
4
1
9
4
^
2
8
5
c
D
a
y
4
6
2
4
5
^
2
2
2
2
7
^
1
8
5
.5
^
0
.3
5
.4
^
0
.2
c
1
3
.0
^
0
.5
1
4
.8
^
0
.7
1
3
3
^
1
3
1
2
8
^
1
0
c
3
.6
^
0
.7
c
2
.0
^
0
.3
c
2
.0
^
0
.2
c
3
9
8
0
^
2
0
3
c
D
a
ta
a
re
p
re
s
e
n
te
d
a
s
m
e
a
n
s
^
S
.E
.M
.
†
N
o
te
th
a
t
th
e
a
s
s
a
y
d
id
n
o
t
d
is
ti
n
g
u
is
h
b
e
tw
e
e
n
e
n
d
o
g
e
n
o
u
s
le
p
ti
n
a
n
d
P
E
G
-O
B
.
F
o
r
d
if
fe
re
n
c
e
s
c
o
m
p
a
re
d
to
b
a
s
e
lin
e
(d
a
y
1
):
a
P
,
0
.0
5
,
b
P
,
0
.0
1
,
c
P
,
0
.0
0
1
.
PEG-OB effects during human semi-starvation 653EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003) 148
www.eje.org
estradiol levels and corrected the blunted LH response
to luteinizing hormone-releasing hormone. No clinical
or key regulatory effects of treatment were observed
on thyroid or adrenocortical function (27).
Taken together, our results seem to support the
hypothesis that the reduction in leptin is one of the
factors that may be responsible for the fasting-induced
inhibition of the reproductive axis and subsequent
impaired fertility in humans (28, 29).
Several limitations of our study are of note that
could account for the limited effect of leptin observed
in this study. The lowest leptin levels reached in the
placebo group in this study are still higher than the
leptin levels found in the syndromes mentioned
above. Furthermore, reproductive function is known
to continue in males under limited energy availability
in which it is completely blocked in females, suggesting
that female reproduction is more sensitive to
nutritional deprivation (30, 31). Both observations
could account for the limited effect of leptin therapy
on reproductive hormones found in this study with
severe energy-restricted overweight males. Also the
serum leptin levels achieved in this pharmacological
study are supraphysiological. Recent studies suggest
that the threshold for the various responses to leptin
is set at different levels. Some evidence suggests that
especially the effects on neuroendocrine function eli-
cited by hyperleptinemia might differ from those
caused by leptin in the physiological range (32, 33).
Finally, more subtle effects on these dynamic
neuroendocrine axes might have been revealed by
direct measurements of diurnal variations or the pulsa-
tility of secretory patterns.
In conclusion, we demonstrated that although
weekly 80 mg s.c. PEG-OB administration to severe
energy-restricted healthy overweight men led to
significant additional weight loss after 6 weeks, it did
not reverse the fasting-induced changes in the thyroid,
corticotropic, somatotropic axes, and sympathetic ner-
vous system activity. However, the drop in mean LH
levels when adjusted for weight loss was attenuated
in the PEG-OB group compared with the placebo
group. This result suggests that a reduced level of
leptin accompanying food restriction might be a
component of the fasting-induced neuroendocrine
inhibition of the human reproductive axis.
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Table 3 Changes in mean (5-h) serum concentrations (pools) for all subjects.
Placebo (n ¼ 10) PEG-OB (n ¼ 12)
Day 2 14 Day 25 Day 2 14 Day 25
Cortisol (nmol/l) 204.2^24.0 240.8^19.4 214.5^17.6 241.8^18.4
GH (mU/l) 0.40^0.12 1.75^0.41b 0.55^0.21 2.17^0.44b
TSH (mU/l) 1.24^0.07 1.09^0.14 1.18^0.14 1.09^0.15
PRL (U/l) 0.121^0.010 0.101^0.013a 0.135^0.013 0.126^0.015
LH (U/l) 3.72^0.75 3.07^0.70a 3.63^0.47 3.44^0.39
FSH (U/l) 4.28^1.45 4.01^1.46 3.71^0.72 3.35^0.48
Total testosterone (nmol/l) 19.45^2.03 19.08^1.26 19.33^1.06 22.17^1.02a
SHBG (nmol/l) 20.2^2.4 38.4^6.3b 20.8^1.8 38.5^2.9c
Albumin (g/l) 40.8^0.6 40.3^0.9 41.3^0.5 40.5^0.7
Free testosterone† (pmol/l) 438.4^32.1 295.7^20.1b 432.2^25.3 345.5^20.5b
Data are presented as means^S.E.M.
† Free testosterone was calculated from plasma total testosterone, SHBG and albumin (see Subjects and methods section).
For differences compared to baseline (day 214): aP , 0.05, bP , 0.01, cP , 0.001.
Figure 1 Percentage change in 5-h mean LH concentrations as a
function of percentage change in weight plotted for the PEG-OB
group (X) and placebo group (A). The regression line of the
PEG-OB group is significantly different from the regression line of
the placebo group (Multiple-linear-regression analysis: P ¼ 0.03).
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